RE:RE:RE:RE:RE:RE:RE:NASH in the ATM ProspectusLooking at comps, you could justify $200mil given how they got there. But a stock market could give +/- 50% around that as we've seen. I don't think there's really a lot in the current THTX valuation for that asset. Maybe $50-75 mil if I still use my $100-150mil oncology option value. It's all guesswork, but I don't think we can ascribe the same kind of value we see others imputing to some of the other NASH assets.
qwerty22 wrote: I think you value them as strongly entering 2b or a risky shot at a registrational trial. I think there is certainty about that uncertainty because they went through the Ph3 regulatory process and at a minimum the fda said they were registrationally ready (with some caveats).
What would you value that asset in the depressed NASH market? $300 mil? More?
I think this is what going through the fda process and completing it gives them, it sets a baseline on the value of the program based on the FDA's decision making process rather than difficult to understand concepts like 'the totality of the data'. Hopefully a partner appreciates that, eventually when/if the program gets started then the market will appreciate it too.